Optimizing chemotherapy and radiotherapy in locally advanced non-small cell lung cancer

被引：7

作者：

Arriagada, R ^{[1
]}

机构：

[1] INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 1997年 / 11卷 / 03期

关键词：

D O I：

10.1016/S0889-8588(05)70444-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In recent years, three treatment methods have been shown to improve overall survival of patients with locally advanced non-small cell lung cancer. These are: sequential combined radiotherapy and cisplatin-based chemotherapy, concurrent administration of cisplatin and thoracic radiotherapy, and accelerated hyper fractionated radiotherapy. Optimization of results can be attained by integrating, these three treatment approaches.

引用

页码：461 / +

页数：1

共 39 条

[1] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].

ALBAIN, KS ;

RUSCH, VW ;

CROWLEY, JJ ;

RICE, TW ;

TURRISI, AT ;

WEICK, JK ;

LONCHYNA, VA ;

PRESANT, CA ;

MCKENNA, RJ ;

GANDARA, DR ;

FOSMIRE, H ;

TAYLOR, SA ;

STELZER, KJ ;

BEASLEY, KR ;

LIVINGSTON, RB .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892

[2]

ALBERTI W, 1995, BRIT MED J, V311, P899

[3]

ANSARI R, 1991, P AN M AM SOC CLIN, V10, P241

[4] EFFECT OF CHEMOTHERAPY ON LOCALLY ADVANCED NON-SMALL-CELL LUNG-CARCINOMA - A RANDOMIZED STUDY OF 353 PATIENTS [J].

ARRIAGADA, R ;

LECHEVALIER, T ;

QUOIX, E ;

RUFFIE, P ;

DECREMOUX, H ;

DOUILLARD, JY ;

TARAYRE, M ;

PIGNON, JP ;

LAPLANCHE, A .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (06) :1183-1190

[5] COMPETING EVENTS DETERMINING RELAPSE-FREE SURVIVAL IN LIMITED SMALL-CELL LUNG-CARCINOMA [J].

ARRIAGADA, R ;

KRAMAR, A ;

LECHEVALIER, T ;

DECREMOUX, H .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :447-451

[6] A PHASE-III STUDY OF ACCELERATED RADIOTHERAPY WITH AND WITHOUT CARBOPLATIN IN NONSMALL CELL LUNG-CANCER - AN INTERIM TOXICITY ANALYSIS OF THE FIRST 100 PATIENTS [J].

BALL, D ;

BISHOP, J ;

SMITH, J ;

CRENNAN, E ;

OBRIEN, P ;

DAVIS, S ;

RYAN, G ;

JOSEPH, D ;

WALKER, Q .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (02) :267-272

[7]

CHOY H, 1996, P AN M AM SOC CLIN, V15, P371

[8] A RANDOMIZED PHASE-I/II TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH TOTAL DOSES OF 60.0 GY TO 79.2 GY - POSSIBLE SURVIVAL BENEFIT WITH GREATER-THAN-OR-EQUAL-TO 69.6 GY IN FAVORABLE PATIENTS WITH RADIATION-THERAPY ONCOLOGY GROUP STAGE-III NON-SMALL-CELL LUNG-CARCINOMA - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 83-11 [J].

COX, JD ;

AZARNIA, N ;

BYHARDT, RW ;

SHIN, KH ;

EMAMI, B ;

PAJAK, TF .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1543-1555

[9] INTERRUPTIONS OF HIGH-DOSE RADIATION-THERAPY DECREASE LONG-TERM SURVIVAL OF FAVORABLE PATIENTS WITH UNRESECTABLE NONSMALL CELL-CARCINOMA OF THE LUNG - ANALYSIS OF 1244 CASES FROM 3 RADIATION-THERAPY ONCOLOGY GROUP (RTOG) TRIALS [J].

COX, JD ;

PAJAK, TF ;

ASBELL, S ;

RUSSELL, AH ;

PEDERSON, J ;

BYHARDT, RW ;

EMAMI, B ;

ROACH, M .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (03) :493-498

[10]

COY P, 1970, CANCER, V26, P803, DOI 10.1002/1097-0142(197010)26:4<803::AID-CNCR2820260410>3.0.CO

← 1 2 3 4 →